Summary of background medications active at time of chronic GVHD diagnosis
| Background therapy . | N . | Percentage(of 745) . |
|---|---|---|
| None/not definable | 247 | 33.2% |
| Nonprednisone | ||
| CNI only | 235 | 31.5% |
| Tacrolimus | 151 | 20.2% |
| Cyclosporine | 84 | 11.2% |
| MMF or MTX ± CNI without sirolimus | 24 | 3.2% |
| MMF-based | 23 | 3.1% |
| MTX-based | 1 | 0.1% |
| Sirolimus ± CNI without MMF | 50 | 6.7% |
| Other/rare combinations ± CNI | 21 | 2.8% |
| Imatinib, nilotinib, dasatinib | 8 | 1.0% |
| Sirolimus, lenalidomide, cyclosporine | 1 | 0.1% |
| Velcade, cyclosporine | 1 | 0.1% |
| MMF, sirolimus | 1 | 0.1% |
| Rituximab | 1 | 0.1% |
| ECP, tacrolimus | 1 | 0.1% |
| MMF, sirolimus, tacrolimus | 3 | 0.4% |
| MTX, tacrolimus | 1 | 0.1% |
| Prednisone only | 40 | 5.4% |
| Prednisone + other agent(s) | ||
| Prednisone ± CNI | 77 | 10.3% |
| Prednisone, cyclosporine | 25 | 3.4% |
| Prednisone, cyclosporine, tacrolimus | 2 | 0.3% |
| Prednisone, tacrolimus | 50 | 6.7% |
| Prednisone + sirolimus ± CNI | 9 | 1.2% |
| Prednisone + MMF or MTX ± CNI | 23 | 3.1% |
| Prednisone, MMF, cyclosporine | 11 | 1.5% |
| Prednisone, MMF | 7 | 0.9% |
| Prednisone, MMF, tacrolimus | 4 | 0.5% |
| Prednisone, MTX, MMF, tacrolimus | 1 | 0.1% |
| Prednisone + ECP ± CNI | 8 | 1.1% |
| Prednisone, ECP, cyclosporine | 1 | 0.1% |
| Prednisone, ECP, sirolimus | 1 | 0.1% |
| Prednisone, ECP, tacrolimus | 4 | 0.5% |
| Prednisone, ECP, MMF, tacrolimus | 2 | 0.3% |
| Prednisone + other combinations | 8 | 1.1% |
| Prednisone, cyclosporine, imatinib | 2 | 0.3% |
| Prednisone, imatinib | 1 | 0.1% |
| Prednisone, MMF, sirolimus | 3 | 0.4% |
| Prednisone, tacrolimus, dasatinib | 1 | 0.1% |
| Prednisone, tacrolimus, MMF, sirolimus | 1 | 0.1% |
| Topical only | 3 | 0.4% |
| Montelukast | 3 | 0.4% |
| Background therapy . | N . | Percentage(of 745) . |
|---|---|---|
| None/not definable | 247 | 33.2% |
| Nonprednisone | ||
| CNI only | 235 | 31.5% |
| Tacrolimus | 151 | 20.2% |
| Cyclosporine | 84 | 11.2% |
| MMF or MTX ± CNI without sirolimus | 24 | 3.2% |
| MMF-based | 23 | 3.1% |
| MTX-based | 1 | 0.1% |
| Sirolimus ± CNI without MMF | 50 | 6.7% |
| Other/rare combinations ± CNI | 21 | 2.8% |
| Imatinib, nilotinib, dasatinib | 8 | 1.0% |
| Sirolimus, lenalidomide, cyclosporine | 1 | 0.1% |
| Velcade, cyclosporine | 1 | 0.1% |
| MMF, sirolimus | 1 | 0.1% |
| Rituximab | 1 | 0.1% |
| ECP, tacrolimus | 1 | 0.1% |
| MMF, sirolimus, tacrolimus | 3 | 0.4% |
| MTX, tacrolimus | 1 | 0.1% |
| Prednisone only | 40 | 5.4% |
| Prednisone + other agent(s) | ||
| Prednisone ± CNI | 77 | 10.3% |
| Prednisone, cyclosporine | 25 | 3.4% |
| Prednisone, cyclosporine, tacrolimus | 2 | 0.3% |
| Prednisone, tacrolimus | 50 | 6.7% |
| Prednisone + sirolimus ± CNI | 9 | 1.2% |
| Prednisone + MMF or MTX ± CNI | 23 | 3.1% |
| Prednisone, MMF, cyclosporine | 11 | 1.5% |
| Prednisone, MMF | 7 | 0.9% |
| Prednisone, MMF, tacrolimus | 4 | 0.5% |
| Prednisone, MTX, MMF, tacrolimus | 1 | 0.1% |
| Prednisone + ECP ± CNI | 8 | 1.1% |
| Prednisone, ECP, cyclosporine | 1 | 0.1% |
| Prednisone, ECP, sirolimus | 1 | 0.1% |
| Prednisone, ECP, tacrolimus | 4 | 0.5% |
| Prednisone, ECP, MMF, tacrolimus | 2 | 0.3% |
| Prednisone + other combinations | 8 | 1.1% |
| Prednisone, cyclosporine, imatinib | 2 | 0.3% |
| Prednisone, imatinib | 1 | 0.1% |
| Prednisone, MMF, sirolimus | 3 | 0.4% |
| Prednisone, tacrolimus, dasatinib | 1 | 0.1% |
| Prednisone, tacrolimus, MMF, sirolimus | 1 | 0.1% |
| Topical only | 3 | 0.4% |
| Montelukast | 3 | 0.4% |